RecruitingEarly Phase 1NCT05874310
Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraocular Administration of FT-002 in Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa.
Sponsor
Frontera Therapeutics
Enrollment
18 participants
Start Date
Feb 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).
Eligibility
Sex: MALEMin Age: 8 YearsMax Age: 45 Years
Inclusion Criteria1
- Subjects that are willing and able to follow study procedures; 2.Males aged 8-45 years old at the time of signing the Informed Consent Form; 4.Subjects who are confirmed with variants of RPGR ;
Exclusion Criteria1
- Have other retinal degenerative diseases, such as retinal degeneration caused by other known Inherited retinal disease gene variants or previously received an gene therapy product.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
GENETICFT-002
Comparison of different dosages of FT-002
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05874310